Jan Rusz
Research Interests
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
Articles (20)
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Objective This study assessed the relationship between speech and language impairment and outcome in a multicenter cohort of isolated/idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD). Methods Patients with iRBD from 7 centers speaking Czech, English, German, French, and Italian languages underwent a detailed speech assessment at baseline. Story‐tale narratives were transcribed and linguistically annotated using fully automated methods based on automatic speech recognition and natural language processing algorithms, leading to the 3 distinctive linguistic and 2 acoustic patterns of language deterioration and associated composite indexes of their overall severity. Patients were then prospectively followed and received assessments for parkinsonism or dementia during follow‐up. The Cox proportional hazard was performed to evaluate the predictive value of language patterns for phenoconversion over a follow‐up period of 5 years. Results Of 180 patients free of parkinsonism or dementia, 156 provided follow‐up information. After a mean follow‐up of 2.7 years, 42 (26.9%) patients developed neurodegenerative disease. Patients with higher severity of linguistic abnormalities (hazard ratio [HR = 2.35]) and acoustic abnormalities (HR = 1.92) were more likely to develop a defined neurodegenerative disease, with converters having lower content richness (HR = 1.74), slower articulation rate (HR = 1.58), and prolonged pauses (HR = 1.46). Dementia‐first (n = 16) and parkinsonism‐first with mild cognitive impairment (n = 9) converters had higher severity of linguistic abnormalities than parkinsonism‐first with normal cognition converters (n = 17). Interpretation Automated language analysis might provide a predictor of phenoconversion from iRBD into synucleinopathy subtypes with cognitive impairment, and thus can be used to stratify patients for neuroprotective trials. ANN NEUROL 2024;95:530–543
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Collaborators (8)
Elina Tripoliti
UCL Institute of Neurology, University College London
Tabea Thies
University of Cologne
David Kemlink
-
Evžen Růžička
Head of department
General Faculty Hospital, 1st Medical Faculty of Charles University
Petr Dusek
-
Karel Šonka
Professor, senior researcher
Charles University, First Faculty of Medicine
Radim Krupicka
Czech Technical University in Prague
Jan Švihlík
Associate Professor
University of Chemistry and Technology
Make your next move.
Prepare your application
Review drafts before you send them.